On the surface this is a classic example of anti-competitive behaviour in a duopolistic market.
The CMA has alleged that Concordia and Actavis signed illegal agreements which enabled high prices for a life-saving drug to be prolonged. Naturally the announcement has brought a wave of criticism for the businesses involved because the cost of higher prices for drugs routinely used in the NHS are ultimately paid for by the taxpayer.
© 2022 Tutor2u Limited. Company Reg no: 04489574. VAT reg no 816865400.